Bristol Myers Squibb Q1 FY26: where the revenue came from and where it went
The whole income statement of Bristol Myers Squibb for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- Apr 30, 2026
Revenue$11.5B
+3% year over year
Gross profit$8.1B
70% margin
Operating profit−$0.5B
−5% margin
Net profit$2.7B
23% margin
Net profit is larger than what operations earned, because the statement adds $3.8B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 11.5 | 100% | +3% |
| Eliquis | 4.1 | 36% | |
| Opdivo | 2.1 | 19% | |
| Other revenue | 2.1 | 18% | |
| Orencia | 0.8 | 7% | |
| Yervoy | 0.7 | 6% | |
| Other growth products | 0.6 | 5% | |
| Reblozyl | 0.6 | 5% | |
| Pomalyst/Imnovid | 0.5 | 4% | |
| Cost of revenue | −3.4 | 30% | |
| Gross profit | 8.1 | 70% margin | −3pp |
| R&D | −2.6 | 23% | +3pp |
| SG&A | −1.6 | 14% | +0pp |
| Other | −4.3 | 38% | |
| Operating profit | −0.5 | −5% margin | +0pp |
| Other income, net | 3.8 | ||
| Tax | −0.6 | ||
| Net profit | 2.7 | 23% margin | +1pp |
220 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest